Second-line treatment for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with colorectal cancer that has spread or returned after initial treatment.
- You received a specific first-line therapy including fluoropyrimidine, oxaliplatin, and a targeted drug (bevacizumab or cetuximab).
- You have at least one tumor that can be measured on scans.
- Your major organs (bone marrow, kidneys, liver) are working well enough on blood tests.
- You have not had irinotecan as part of your first treatment.
- You do not have certain gene changes that make immunotherapy the better option (dMMR/MSI-H).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—bevacizumab and trifluridine/tipiracil—given together to see if it lowers the risk of a serious drop in white blood cells (neutropenia) in people with advanced colorectal cancer. The goal is to make treatment safer and more tolerable.
This study tests a combination of two drugs, trifluridine and tipiracil, for people whose colorectal cancer has spread to other parts of the body. The goal is to see how well this treatment works in real life and if it can help you live longer or feel better.
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.